Philips will showcase its latest cardiac care innovations at the European Society of Cardiology (ESC) Congress 2019, Aug. 31–Sept. 4 in Paris, France. At the congress, Philips is showcasing Release 5.0 of its Epiq CVx cardiology platform for the first time in Europe. The platform includes automated applications for 2-D assessment of the heart, as well as robust 3-D right ventricle volume and ejection fraction measurements, making accurate exams faster and easier to conduct. Philips also announced that it is collaborating with digital health company LindaCare to combine the latter’s OnePulse cloud-based solution for the remote monitoring of patients with cardiac implantable electronic devices (CIEDs) with the Philips IntelliSpace Cardiovascular informatics platform.

InfoBionic’s MoMe Kardia remote ECG monitor is an example of the newer generation devices that are replacing traditional Holter monitors. It has a single button for patients to create an alert when they are experiencing arrhythmia symptoms.
This is the Cardea Solo wearable ECG monitor. It uses a retrievable data pod that stores all data for the time the patient wears the device. The outside case is disposable.
An example of one of the new generation wearable cardiac monitors that sticks onto the patient's chest and does not require wires leads. These devices continuously record data, which can be reviewed online by the physician.

Until recently, cardiologists trying to diagnose and treat arrhythmias have had to deal with technological limitations in data transmission, storage and analysis. We have had to rely on third-party independent diagnostic and testing facilities (IDTFs) to read remote cardiac monitoring data and then phone, fax or e-mail the important events back to the practice. 
 
The Blind Spots in Remote Cardiac Monitoring 

Use of the Internet of Things (IoT) is booming, with IHS Markit forecasting there will be 73 billion connected devices in use around the world by 2025. IoT technology has moved beyond speakers and smart fridges and is increasingly being utilized for critical applications across the healthcare industry like insulin delivery devices, connected inhalers and even cancer treatments.

In the near future, doctors may be able to apply artificial intelligence (AI) to electrocardiogram data in order to measure overall health status, according to new research. The study was published in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association.

 

Atrial fibrillation, or Afib, kills about 130,000 people worldwide every year. It also affects 3 to 6 million people in the United States alone and is a leading factor in prolonged hospital stays, according to the Centers for Disease Control and Prevention.

Ashutosh Banerjee, general manager of GE Healthcare Diagnostic Cardiology

Merit Medical Systems Inc. announced the U.S. commercial launch of the PreludeSync Evo radial compression device. The PreludeSync Evo is a sterile, single-use, disposable device used to assist in gaining hemostasis of the arterial percutaneous access site following catheterization procedures.

FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices

The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-coated devices used to treat peripheral artery disease (PAD) following its review of long-term follow-up clinical data. The agency said five-year results from three randomized trials showed an increased mortality rate in patients treated with these devices compared to those treated with uncoated devices. While these data provide reason for caution, the FDA noted that the devices still provide documented short-term benefits, and healthcare providers should consider all options for their PAD patients.

AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip left atrial appendage (LAA) management devices. These include changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now